KRT14 and metabolic disease: To evaluate the effects of CDCA on metabolic disorders in K14-VEGF-A-transgenic mice, we treated 3-month-old K14-VEGF-A-transgenic mice with vehicle or CDCA by oral gavage daily for a period of 40 days (Figure 6A).